Both mitral and tricuspid regurgitations are quite common in clinical practice. They share etiologies and treatment strategies. Recently, a lot attention has been put on tricuspid regurgitation and its impact on patients outcomes. New pathophysiological and grading concepts has been introduced. Percutaneous transcatheter technologies for both atrioventricular valves are studied extensively and have reached randomized controlled trials stage.